RNA replicons - A new approach for influenza virus immunoprophylaxis

Viruses

Volumn 2, Issue 2, 2010, Pages 413-434

  Zimmer, Gert ^a  

^a INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

Author keywords

Alphavirus; Biosafety; Cellular immunity; Heterosubtypic immunity; Mucosal immunity; RNA replicon; Vaccine; Vesicular stomatitis virus

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; INTERFERON; LIVE VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIGEN; RECOMBINANT VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS SIALIDASE; VIRUS VECTOR;

ALPHA VIRUS; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; AVIAN INFLUENZA VIRUS; CELLULAR IMMUNITY; COLD ACCLIMATIZATION; CYTOSOL; DENDRITIC CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H5N1; MEDICAL LITERATURE; NONHUMAN; REPLICON; REVIEW; RNA REPLICATION; RNA VIRUS; VESICULAR STOMATITIS VIRUS; VIRUS VIRULENCE;

ALPHAVIRUS; ORTHOMYXOVIRIDAE; RNA VIRUSES; VESICULAR STOMATITIS VIRUS;

EID: 79952081332     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2020413     Document Type: Review

References (87)

1. Rothberg, M.B.; Haessler, S.D.; Brown, R.B. Complications of viral influenza. Am. J. Med. 2008, 121, 258-264.
2. Carrat, F.; Flahault, A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007, 25, 6852-6862.
3. Palache, B. New vaccine approaches for seasonal and pandemic influenza. Vaccine 2008, 26, 6232-6236.
4. Gambotto, A.; Barratt-Boyes, S.M.; de Jong, M.D.; Neumann, G.; Kawaoka, Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet 2008, 371, 1464-1475.
5. Webby, R.J.; Webster, R.G.; Richt, J.A. Influenza viruses in animal wildlife populations. Curr. Top. Microbiol. Immunol. 2007, 315, 67-83.
6. Weingartl, H.M.; Albrecht, R.A.; Lager, K.M.; Babiuk, S.; Marszal, P.; Neufeld, J.; Embury-Hyatt, C.; Lekcharoensuk, P.; Tumpey, T.M.; Garcia-Sastre, A.; Richt, J.A. Experimental infection of pigs with the human 1918 pandemic influenza virus. J. Virol. 2009, 83, 4287-4296.
7. Gerdil, C. The annual production cycle for influenza vaccine. Vaccine 2003, 21, 1776-1779.
8. Rimmelzwaan, G.F.; Fouchier, R.A.; Osterhaus, A.D. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol. 2007, 18, 529-536.
9. McMurry, J.A.; Johansson, B.E.; De Groot, A.S. A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A. Hum. Vaccin. 2008, 4, 148-157.
10. de Jong, J.C.; Beyer, W.E.; Palache, A.M.; Rimmelzwaan, G.F.; Osterhaus, A.D. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J. Med. Virol. 2000, 61, 94-99.
11. Kreijtz, J.H.; Osterhaus, A.D.; Rimmelzwaan, G.F. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum. Vaccin. 2009, 5, 126-135.
12. Wareing, M.D.; Tannock, G.A. Live attenuated vaccines against influenza; an historical review. Vaccine 2001, 19, 3320-3330.
13. Beyer, W.E.; Palache, A.M.; de Jong, J.C.; Osterhaus, A.D. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002, 20, 1340-1353.
14. Powell, T.J.; Strutt, T.; Reome, J.; Hollenbaugh, J.A.; Roberts, A.D.; Woodland, D.L.; Swain, S.L.; Dutton, R.W. Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J. Immunol. 2007, 178, 1030-1038.
15. Karron, R.A.; Talaat, K.; Luke, C.; Callahan, K.; Thumar, B.; Dilorenzo, S.; McAuliffe, J.; Schappell, E.; Suguitan, A.; Mills, K.; Chen, G.; Lamirande, E.; Coelingh, K.; Jin, H.; Murphy, B.R.; Kemble, G.; Subbarao, K. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009, 27, 4953-4960.
16. Ambrose, C.S.; Luke, C.; Coelingh, K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respi. Viruses 2008, 2, 193-202.
17. Liniger, M.; Zuniga, A.; Naim, H.Y. Use of viral vectors for the development of vaccines. Expert Rev. Vaccines 2007, 6, 255-266.
18. Minor, P. Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication. Vaccine 2009, 27, 2649-2652.
19. Ehrenfeld, E.; Modlin, J.; Chumakov, K. Future of polio vaccines. Expert Rev. Vaccines 2009, 8, 899-905.
20. Dory, D.; Gravier, R.; Jestin, A. Risk assessment in new and conventional vaccines. Dev. Biol. (Basel) 2006, 126, 253-259; discussion 327.
21. Vyas, J.M.; Van der Veen, A.G.; Ploegh, H.L. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 2008, 8, 607-618.
22. Nakhaei, P.; Genin, P.; Civas, A.; Hiscott, J. RIG-I-like receptors: Sensing and responding to RNA virus infection. Semin. Immunol. 2009.
23. Randall, R.E.; Goodbourn, S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 2008, 89, 1-47.
24. Powers, C.; DeFilippis, V.; Malouli, D.; Fruh, K. Cytomegalovirus immune evasion. Curr. Top. Microbiol. Immunol. 2008, 325, 333-359.
25. Seet, B.T.; Johnston, J.B.; Brunetti, C.R.; Barrett, J.W.; Everett, H.; Cameron, C.; Sypula, J.; Nazarian, S.H.; Lucas, A.; McFadden, G. Poxviruses and immune evasion. Annu. Rev. Immunol. 2003, 21, 377-423.
26. Rayner, J.O.; Dryga, S.A.; Kamrud, K.I. Alphavirus vectors and vaccination. Rev. Med. Virol. 2002, 12, 279-296.
27. Atkins, G.J.; Fleeton, M.N.; Sheahan, B.J. Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev Mol Med 2008, 10, e33.
28. Pijlman, G.P.; Suhrbier, A.; Khromykh, A.A. Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Expert Opin. Biol. Ther. 2006, 6, 135-145.
29. Widman, D.G.; Ishikawa, T.; Fayzulin, R.; Bourne, N.; Mason, P.W. Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. Vaccine 2008, 26, 2762-2771.
30. Suzuki, R.; Winkelmann, E.R.; Mason, P.W. Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2. J. Virol. 2009, 83, 1870-1880.
31. Gehrke, R.; Heinz, F.X.; Davis, N.L.; Mandl, C.W. Heterologous gene expression by infectious and replicon vectors derived from tick-borne encephalitis virus and direct comparison of this flavivirus system with an alphavirus replicon. J. Gen. Virol. 2005, 86, 1045-1053.
32. Vignuzzi, M.; Gerbaud, S.; van der Werf, S.; Escriou, N. Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein. J. Gen. Virol. 2001, 82, 1737-1747.
33. Vignuzzi, M.; Gerbaud, S.; van der Werf, S.; Escriou, N. Expression of a membrane-anchored glycoprotein, the influenza virus hemagglutinin, by dicistronic replicons derived from the poliovirus genome. J. Virol. 2002, 76, 5285-5290.
34. Fleeton, M.N.; Chen, M.; Berglund, P.; Rhodes, G.; Parker, S.E.; Murphy, M.; Atkins, G.J.; Liljestrom, P. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J. Infect. Dis. 2001, 183, 1395-1398.
35. Driver, D.A.; Latham, E.M.; Polo, J.M.; Belli, B.A.; Banks, T. A.; Chada, S.; Brumm, D.; Chang, S.M.; Mento, S.J.; Jolly, D.J. et al. Layered amplification of gene expression with a DNA gene delivery system. Ann. NY Acad. Sci. 1995, 772, 261-264.
36. Berglund, P.; Smerdou, C.; Fleeton, M.N.; Tubulekas, I.; Liljestrom, P. Enhancing immune responses using suicidal DNA vaccines. Nat. Biotechnol. 1998, 16, 562-565.
37. Liljestrom, P.; Garoff, H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (NY) 1991, 9, 1356-1361.
38. Bredenbeek, P.J.; Frolov, I.; Rice, C.M.; Schlesinger, S. Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J. Virol. 1993, 67, 6439-6446.
39. Pushko, P.; Parker, M.; Ludwig, G.V.; Davis, N.L.; Johnston, R.E.; Smith, J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997, 239, 389-401.
40. Schnell, M.J.; Mebatsion, T.; Conzelmann, K.K. Infectious rabies viruses from cloned cDNA. EMBO J. 1994, 13, 4195-4203.
41. Li, H.O.; Zhu, Y.F.; Asakawa, M.; Kuma, H.; Hirata, T.; Ueda, Y.; Lee, Y.S.; Fukumura, M.; Iida, A.; Kato, A.; Nagai, Y.; Hasegawa, M. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J. Virol. 2000, 74, 6564-6569.
42. Inoue, M.; Tokusumi, Y.; Ban, H.; Kanaya, T.; Shirakura, M.; Tokusumi, T.; Hirata, T.; Nagai, Y.; Iida, A.; Hasegawa, M. A new Sendai virus vector deficient in the matrix gene does not form virus particles and shows extensive cell-to-cell spreading. J. Virol. 2003, 77, 6419-6429.
43. Inoue, M.; Tokusumi, Y.; Ban, H.; Kanaya, T.; Tokusumi, T.; Nagai, Y.; Iida, A.; Hasegawa, M. Nontransmissible virus-like particle formation by F-deficient sendai virus is temperature sensitive and reduced by mutations in M and HN proteins. J. Virol. 2003, 77, 3238-3246.
44. Inoue, M.; Tokusumi, Y.; Ban, H.; Shirakura, M.; Kanaya, T.; Yoshizaki, M.; Hironaka, T.; Nagai, Y.; Iida, A.; Hasegawa, M. Recombinant Sendai virus vectors deleted in both the matrix and the fusion genes: efficient gene transfer with preferable properties. J. Gene Med. 2004, 6, 1069-1081.
45. Yoshizaki, M.; Hironaka, T.; Iwasaki, H.; Ban, H.; Tokusumi, Y.; Iida, A.; Nagai, Y.; Hasegawa, M.; Inoue, M. Naked Sendai virus vector lacking all of the envelope-related genes: reduced cytopathogenicity and immunogenicity. J. Gene Med. 2006, 8, 1151-1159.
46. Bernloehr, C.; Bossow, S.; Ungerechts, G.; Armeanu, S.; Neubert, W.J.; Lauer, U.M.; Bitzer, M. Efficient propagation of single gene deleted recombinant Sendai virus vectors. Virus Res. 2004, 99, 193-197.
47. Takada, A.; Robison, C.; Goto, H.; Sanchez, A.; Murti, K. G.; Whitt, M.A.; Kawaoka, Y. A system for functional analysis of Ebola virus glycoprotein. Proc. Natl. Acad. Sci. USA 1997, 94, 14764-14769.
48. Roberts, A.; Buonocore, L.; Price, R.; Forman, J.; Rose, J.K. Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol. 1999, 73, 3723-3732.
49. Hanika, A.; Larisch, B.; Steinmann, E.; Schwegmann-Wessels, C.; Herrler, G.; Zimmer, G. Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. J. Gen. Virol. 2005, 86, 1455-1465.
50. Kalhoro, N.H.; Veits, J.; Rautenschlein, S.; Zimmer, G. A recombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1). Vaccine 2009, 27, 1174-1183.
51. Spann, K.M.; Collins, P.L.; Teng, M.N. Genetic recombination during coinfection of two mutants of human respiratory syncytial virus. J. Virol. 2003, 77, 11201-11211.
52. Collins, P.L.; Bukreyev, A.; Murphy, B.R. What are the risks--hypothetical and observed--of recombination involving live vaccines and vaccine vectors based on nonsegmented negative-strain RNA viruses? J. Virol. 2008, 82, 9805-9806.
53. Raju, R.; Subramaniam, S.V.; Hajjou, M. Genesis of Sindbis virus by in vivo recombination of nonreplicative RNA precursors. J. Virol. 1995, 69, 7391-7401.
54. Gallei, A.; Pankraz, A.; Thiel, H.J.; Becher, P. RNA recombination in vivo in the absence of viral replication. J. Virol. 2004, 78, 6271-6281.
55. Zhou, X.; Berglund, P.; Rhodes, G.; Parker, S.E.; Jondal, M.; Liljestrom, P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 1994, 12, 1510-1514.
56. Zhou, X.; Berglund, P.; Zhao, H.; Liljestrom, P.; Jondal, M. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc. Natl. Acad. Sci. USA 1995, 92, 3009-3013.
57. Berglund, P.; Fleeton, M.N.; Smerdou, C.; Liljestrom, P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 1999, 17, 497-507.
58. Yang, S.G.; Wo, J.E.; Li, M.W.; Yu, C.B.; Lv, G.L.; Cao, H.C.; Lu, H.F.; Wang, B.H.; Zhu, H.P.; Li, L.J. Construction and packaging of Semliki forest virus replicon particles efficiently expressing Influenza A virus (H5N1) hemagglutinin. Acta Virol. 2009, 53, 139-141.
59. Hubby, B.; Talarico, T.; Maughan, M.; Reap, E.A.; Berglund, P.; Kamrud, K.I.; Copp, L.; Lewis, W.; Cecil, C.; Norberg, P.; Wagner, J.; Watson, A.; Negri, S.; Burnett, B.K.; Graham, A.; Smith, J.F.; Chulay, J.D. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 2007, 25, 8180-8189.
60. Kapadia, S.U.; Simon, I.D.; Rose, J.K. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. Virology 2008, 376, 165-172.
61. Publicover, J.; Ramsburg, E.; Rose, J.K. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J. Virol. 2005, 79, 13231-13238.
62. Majid, A.M.; Ezelle, H.; Shah, S.; Barber, G.N. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle. J. Virol. 2006, 80, 6993-7008.
63. Kahn, J.S.; Roberts, A.; Weibel, C.; Buonocore, L.; Rose, J.K. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J. Virol. 2001, 75, 11079-11087.
64. Schwartz, J.A.; Buonocore, L.; Roberts, A.; Suguitan, A., Jr.; Kobasa, D.; Kobinger, G.; Feldmann, H.; Subbarao, K.; Rose, J.K. Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology 2007, 366, 166-173.
65. Lee, C.W.; Senne, D.A.; Suarez, D.L. Effect of vaccine use in the evolution of Mexican lineage H5N2 avian influenza virus. J. Virol. 2004, 78, 8372-8381.
66. Lee, C.W.; Suarez, D.L. Avian influenza virus: prospects for prevention and control by vaccination. Anim. Health Res. Rev. 2005, 6, 1-15.
67. Schultz-Cherry, S.; Dybing, J.K.; Davis, N.L.; Williamson, C.; Suarez, D.L.; Johnston, R.; Perdue, M.L. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 2000, 278, 55-59.
68. Sylte, M.J.; Hubby, B.; Suarez, D.L. Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine 2007, 25, 3763-3772.
69. Rott, R.; Becht, H.; Orlich, M. The significance of influenza virus neuraminidase in immunity. J. Gen. Virol. 1974, 22, 35-41.
70. Pavlova, S.P.; Veits, J.; Keil, G.M.; Mettenleiter, T.C.; Fuchs, W. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious aryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase. Vaccine 2009, 27, 773-785.
71. Salomon, R.; Webster, R.G. The influenza virus enigma. Cell 2009, 136, 402-410.
72. Huber, V.C.; McKeon, R.M.; Brackin, M.N.; Miller, L.A.; Keating, R.; Brown, S.A.; Makarova, N.; Perez, D.R.; Macdonald, G.H.; McCullers, J.A. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin. Vaccine Immunol. 2006, 13, 981-990.
73. Thompson, J.M.; Whitmore, A.C.; Konopka, J.L.; Collier, M.L.; Richmond, E.M.; Davis, N.L.; Staats, H.F.; Johnston, R.E. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc. Natl. Acad. Sci. USA 2006, 103, 3722-3727.
74. Thompson, J.M.; Whitmore, A.C.; Staats, H.F.; Johnston, R. The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine 2008, 26, 4998-5003.
75. Maassab, H.F.; Bryant, M.L. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev. Med. Virol. 1999, 9, 237-244.
76. Jameson, J.; Cruz, J.; Ennis, F.A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J. Virol. 1998, 72, 8682-8689.
77. Boon, A.C.; de Mutsert, G.; van Baarle, D.; Smith, D.J.; Lapedes, A.S.; Fouchier, R.A.; Sintnicolaas, K.; Osterhaus, A.D.; Rimmelzwaan, G.F. Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. J. Immunol. 2004, 172, 2453-2460.
78. Roy, S.; Kobinger, G.P.; Lin, J.; Figueredo, J.; Calcedo, R.; Kobasa, D.; Wilson, J.M. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 2007, 25, 6845-6851.
79. Tucker, S.P.; Compans, R.W. Virus infection of polarized epithelial cells. Adv. Virus Res. 1993, 42, 187-247.
80. Fuller, S.; von Bonsdorff, C.H.; Simons, K. Vesicular stomatitis virus infects and matures only through the basolateral surface of the polarized epithelial cell line, MDCK. Cell 1984, 38, 65-77.
81. Fuller, S.D.; von Bonsdorff, C.H.; Simons, K. Cell surface influenza haemagglutinin can mediate infection by other animal viruses. EMBO J. 1985, 4, 2475-2485.
82. Schnell, M.J.; Buonocore, L.; Kretzschmar, E.; Johnson, E.; Rose, J.K. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc. Natl. Acad. Sci. USA 1996, 93, 11359-11365.
83. Ross, T.M.; Xu, Y.; Bright, R.A.; Robinson, H.L. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat. Immunol. 2000, 1, 127-131.
84. Fiers, W.; Neirynck, S.; Deroo, T.; Saelens, X.; Jou, W.M. Soluble recombinant influenza vaccines. Philos. Trans. R Soc. Lond. B Biol. Sci. 2001, 356, 1961-1963.
85. Bukreyev, A.; Skiadopoulos, M.H.; McAuliffe, J.; Murphy, B.R.; Collins, P.L.; Schmidt, A.C. More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved? Proc. Natl. Acad. Sci. USA 2002, 99, 16987-16991.
86. Nishimoto, K.P.; Laust, A. K.; Wang, K.; Kamrud, K.I.; Hubby, B.; Smith, J.F.; Nelson, E.L. Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells. Viral Immunol. 2007, 20, 88-104.
87. Gardner, J.P.; Frolov, I.; Perri, S.; Ji, Y.; MacKichan, M.L.; zur Megede, J.; Chen, M.; Belli, B.A.; Driver, D.A.; Sherrill, S.; Greer, C.E.; Otten, G.R.; Barnett, S.W.; Liu, M.A.; Dubensky, T.W.; Polo, J.M. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J. Virol. 2000, 74, 11849-11857.